|[February 19, 2013]
Allenex AB: US breakthrough order for Allenex with SBT Resolver™
STOCKHOLM --(Business Wire)--
A leading United States based HLA laboratory has chosen Allenex´s US
distribution company Olerup Inc as their partner for the delivery of
sequence based HLA tissue typing, SBT. This top tier immunogenetics
laboratory has evaluated and validated SBT Resolver™ from the Allenex
partner Conexio Genomics. The lab committed to the use of SBT Resolver™,
and has already subsequently placed an initial order, which also include
the proprietary software Assign™ 3.6+. Yearly sales are estimated at
over two million SEK for 2013.
"This is a breakthrough event and a major step forward regarding our
sales of SBT Resolver™ for HLA typing for bone marrow transplants" says
Anders Karlsson, CEO of Allenex. "We are happy and proud to be able to
meet the expectations from this top HLA laboratory. Timing wise this is
very important since Olerup Inc is currently working intensely with a
number of other large US based typing laboratories undergoing a similar
evaluation process regarding choice of SBT solutions" he cncludes.
Allenex/Olerup Inc (STO:ALNX) has effectively developed a positive US
market presence, as it grows its penetration among the 65 HLA
laboratories that currently use SBT in the US market. Allenex/Olerup and
its partner Conexio Genomics will be the sole source offering Assign™
software after December 31, 2013. Assign™ is the most widely used
software for SBT typing in the US and the latest version (3.6+) of that
software will only be offered to HLA laboratories as a part of the SBT
Resolver™ product solution.
The decision making process for this type of technology is relatively
long, between 6-18 months. An increasing number of US HLA laboratories
are now in an advanced stage of evaluating the SBT Resolver™ offering.
Ten large US laboratories are close to the end of the validation
process, while more than ten labs are in the early stages of evaluating
SBT Resolver™. More laboratories have committed to initiate the
evaluation and validation process during 2013. Allenex/Olerup believes
that several of these will become new customers that will utilize the
SBT Resolver™ solution in the United States, thereby providing the
potential to positively impact bone marrow transplant outcomes.
Allenex AB discloses the information provided herein pursuant to the
Securities Markets Act and /or the Financial Instruments Trading Act.
The information was submitted for publication on Feb 19, 2013, at 11.15
CET. Allenex is a life science-company that develops, manufacture,
market and sell products for safer transplants of organs and bone marrow
on the global market. Allenex is listed on NASDAQ OMX Stockholm Small
Cap (ticker: ALNX). 52 persons are employed in the Allenex group.
This information was brought to you by Cision http://news.cision.com
[ Back To Technology News's Homepage ]